EMEA-001654-PIP01-14-M04 - paediatric investigation plan
tisagenlecleucel
PIPHuman
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 46715
P/0215/2022: EMA decision of 10 June 2022 on the acceptance of a modification of an agreed paediatric investigation plan for tisagenlecleucel (Kymriah), (EMEA-001654-PIP01-14-M04)